AZ MEDI still killin it !!

Discussion in 'AstraZeneca' started by Anonymous, Sep 27, 2014 at 9:09 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    In the case of AstraZeneca's combination, six out of 24 advanced lung cancer patients had adverse events rated as serious, or grade 3/4, and three had events that led to discontinuation of treatment. There was one treatment-related death.
     

  2. Anonymous

    Anonymous Guest

    You lie loser
     
  3. Anonymous

    Anonymous Guest

    They didn't lie, that quote is true, they just didn't tell the whole story.

    "So far, 18 of the patients have been assessed for efficacy and five of these, or 28 percent, had tumor shrinkage, according to research presented at the meeting in Madrid.

    Although direct comparisons are difficult, Antonia said this was much better than the efficacy benefit seen with the Bristol-Myers combination in lung cancer."
     
  4. Anonymous

    Anonymous Guest

    5 with tumor shrinkage 1 killed by medi drug

    notice no one said any of the 5 were cancer free....but the 1 was dead
     
  5. Anonymous

    Anonymous Guest

    The dead one was not just dead, as often happens in cancer studies due to the patients having cancer, but dead from a clearly drug related adverse event. Most of these patients are quite ill and weak however and most would in fact die anyway without successful intervention. There are two few patients in this study for any meaningful statistics but one would be wise to exercise caution in future studies. Doses and regimens and patient qualifications may need to be adjusted for the phase III study.
    Because cancer patients often have a very poor prognosis without drug treatment, the bar is set low for regulatory approvals in the Cancer therapeutic area and this is also why Pharma likes investing in this sector so much. There is a benefit to risk equation here favoring the drug that says why not try the drug even if it may be somewhat risky. The key is there must be great benefit for some patients to make the risk worthwhile to all.
     
  6. Anonymous

    Anonymous Guest

    True, stage 1A has a 49% survival rate at 5 years in small cell lung cancers and stage 4 is 1%, so even in very early stages there is about a 50 percent chance that you're not going to make 5 years. Even small benefits to this cancer could be huge.
     
  7. Anonymous

    Anonymous Guest

    All of these antibody based drugs carry a high risk of an idiosyncratic hyperimmunogenic response, which can lead to the sometimes fatal anaphylactic reaction. Which patients might present this condition can be very hard to predict.
     
  8. Anonymous

    Anonymous Guest

    perfect - 5 look marginally better - 1 absolutely dead from the drug - we rock
     
  9. Anonymous

    Anonymous Guest

    Really? The focus on cancer is never about actually trying to find a cure? You are an idiot.